Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918)

Blood (2015) 126 (23): 811.

https://doi.org/10.1182/blood.V126.23.811.811

Published: 2015

Journal Articles

Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma: A Phase II Trial of the Sarah Cannon Research Institute

Ian W. Flinn, MD, PhD, Dana S. Thompson, MD, Ralph V. Boccia, MD, Gerald Miletello, MD, Andrew Lipman, MD, Douglas Flora, MD, Daniel Cuevas, MD, Steven W. Papish, MD, Jesus G. Berdeja, MD

Blood (2012) 120 (21): 1624.

https://doi.org/10.1182/blood.V120.21.1624.1624

Published: 2012

Journal Articles

Phase II Trial of Ofatumumab (OFA) for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Ian W. Flinn, MD, PhD, William N. Harwin, MD, Patrick Ward, MD, PhD, Habib H. Doss, MD, Steven W. Papish, MD, John D. Hainsworth, MD, Jesus G. Berdeja, MD, John C. Byrd, MD

Blood (2012) 120 (21): 719.

https://doi.org/10.1182/blood.V120.21.719.719

Published: 2012

Journal Articles

A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,

Ian W. Flinn, MD, PhD, William N. Harwin, MD, Inés M. Macias-Pérez, PhD, Patrick S. Tucker, MS, David M. Waterhouse, MD, Steven W. Papish, MD, Jeffrey A. Jones, MD, MPH, John D. Hainsworth, MD, John C. Byrd, MD

Blood (2011) 118 (21): 3912.

https://doi.org/10.1182/blood.V118.21.3912.3912

Published: 2011

Journal Articles

Rapid Prospective Identification of Non-Germinal Center B Cell-Like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients for Targeted Trials: Early Results From PYRAMID, A Phase 2 Randomized Study of R-CHOP ± Bortezomib In Newly Diagnosed Non-GCB DLBCL.

Kevin Doner, MD, Ian W. Flinn, MD, PhD, Brian K. Ulrich, MD, Stephen J. Noga, MD, PhD, Naveed M. Chowhan, MD, Steven W. Papish, MD, Tallat Mahmood, MD, James A Reeves, MD, Nicholas J. Di Bella, MD, Gerald J. Robbins, MD, Radhakrishnan Ramchandren, MD, Sein Aung, MD, William Lawler, MD, Sudha Parasuraman, MD, Maria M. Corvez, BA, George Mulligan, PhD, John P. Leonard, MD

Blood (2010) 116 (21): 1792.

https://doi.org/10.1182/blood.V116.21.1792.1792

Published: 2010

NARROW

Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918)

Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma: A Phase II Trial of the Sarah Cannon Research Institute

Phase II Trial of Ofatumumab (OFA) for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,

Rapid Prospective Identification of Non-Germinal Center B Cell-Like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients for Targeted Trials: Early Results From PYRAMID, A Phase 2 Randomized Study of R-CHOP ± Bortezomib In Newly Diagnosed Non-GCB DLBCL.

Email alerts

ASH Publications

American Society of Hematology

Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918)

Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma: A Phase II Trial of the Sarah Cannon Research Institute

Phase II Trial of Ofatumumab (OFA) for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,

Rapid Prospective Identification of Non-Germinal Center B Cell-Like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients for Targeted Trials: Early Results From PYRAMID, A Phase 2 Randomized Study of R-CHOP ± Bortezomib In Newly Diagnosed Non-GCB DLBCL.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only